CTOs on the Move

Viropro

www.viropro.com

 
Viropro is a Mont-Royal, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.viropro.com
  • 8515 Place Devonshire
    Mont-Royal, QC CAN H4P 2K1
  • Phone: 514.731.8776

Executives

Name Title Contact Details

Similar Companies

Novo Nordisk Canada

Novo Nordisk Canada Inc. is an affiliate of Novo Nordisk A/S, a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,400 employees in 77 countries, and markets its products in more than 165 countries.

Senderra Rx

At Senderra, Patients are people. It`s that simple. We are a specialty pharmacy, but that is where our work begins. We believe success lies in service to others. For this reason, we are dedicated to never losing sight of the people. We believe in the power of technology and data as catalysts to transform and improve processes. Technology is a tool to make our lives easier. For this reason, Senderra invests in our unique technology-driven platform in order to perform best at every turn. Finally, we believe in improved outcomes, no matter with whom we work. That includes Patients, Prescribers, Pharma and Payors. Improving outcomes means we strive to make the kinds of differences that matter.

Cobalt Pharmaceuticals

Cobalt Pharmaceuticals Inc. is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.